A better understanding of the cell-specific differences in the crosstalk between SG formation and NLRP3 activation is crucial for developing prospective targeted DDX3X inhibitors for the treatment of NASH. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.